Emmet McCormack
Overview
Explore the profile of Emmet McCormack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
2044
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tandaric L, Auranen A, Kleinmanns K, Christensen R, Vestrheim Thomsen L, Wogsland C, et al.
Mol Oncol
. 2025 Jan;
PMID: 39887612
Immune checkpoint inhibitors have demonstrated limited efficacy in overcoming immunosuppression in patients with epithelial ovarian cancer (EOC). Although certain patients experience long-term treatment benefit, reliable biomarkers for responder pre-selection and...
2.
Rosselle L, Leray T, Joaquina S, Caulier B, McCormack E, Gelebart P, et al.
STAR Protoc
. 2024 Dec;
6(1):103529.
PMID: 39739533
Chimeric antigen receptors (CARs) are synthetic molecules composed of an extracellular antigen-binding domain and an intracellular signaling domain, leading to tonic signaling and manufacturing challenges. We present a protocol for...
3.
Safont M, Leitch C, Popa M, Gjerstad M, Caulier B, Inderberg E, et al.
STAR Protoc
. 2024 Dec;
5(4):103522.
PMID: 39673705
Patient-derived xenograft (PDX) models of acute myeloid leukemia (AML-PDX) offer advantages over cell line models by capturing the complexity and heterogeneity of patient-derived samples. Here, we present a protocol for...
4.
Ha T, Andresen V, Erikstein B, Popa M, Gullaksen S, Reikvam H, et al.
Br J Haematol
. 2024 Nov;
206(1):109-119.
PMID: 39582120
Resazurin, a phenoxazine used in cell viability assays, acts in vitro as an anti-leukaemic compound through the production of cellular reactive oxygen species (ROS) resulting in mitochondrial dysfunction and cell...
5.
Caulier B, Joaquina S, Gelebart P, Dowling T, Kaveh F, Thomas M, et al.
Cell Rep Med
. 2024 May;
5(6):101572.
PMID: 38754420
Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the peripheral blood. Nearly half of the AML patients relapse after standard...
6.
Casey N, Kleinmanns K, Forcados C, Gelebart P, Joaquina S, Lode M, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38604812
Background: Ovarian cancer (OC) is the leading cause of death from gynecologic malignancies in the Western world. Contributing factors include a high frequency of late-stage diagnosis, the development of chemoresistance,...
7.
Vestrheim Thomsen L, Kleinmanns K, Anandan S, Gullaksen S, Abdelaal T, Iversen G, et al.
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894472
The prognosis of high-grade serous ovarian carcinoma (HGSOC) is poor, and treatment selection is challenging. A heterogeneous tumor microenvironment (TME) characterizes HGSOC and influences tumor growth, progression, and therapy response....
8.
Bartaula-Brevik S, Leitch C, Hernandez-Valladares M, Aasebo E, Berven F, Selheim F, et al.
J Clin Med
. 2023 Sep;
12(17).
PMID: 37685612
Vacuolar ATPase (V-ATPase) is regarded as a possible target in cancer treatment. It is expressed in primary acute myeloid leukemia cells (AML), but the expression varies between patients and is...
9.
Ladds M, van Leeuwen I, Drummond C, Chu S, Healy A, Popova G, et al.
Nat Commun
. 2023 Aug;
14(1):5019.
PMID: 37596290
No abstract available.
10.
Gelebart P, Gjerstad M, Benjaminsen S, Han J, Karlsen I, Safont M, et al.
Blood
. 2023 Jun;
142(17):1478-1493.
PMID: 37339584
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma having a poor overall survival that is in need for the development of new therapeutics. In this study, we report...